Roche, with its feet firmly planted in both pharma and diagnostics, is heavily invested in the search for biomarkers. In addition to looking at their use as a basis for companion diagnostics and patient selection in the treatment setting, the company is highlighting the role of biomarkers as tools for understanding cancer biology and the complexities of the tumor microenvironment to guide research and early development.
Markers like PD-1/PD-L1 unleash huge waves of enthusiasm about their potential for getting drugs to patients, but the complexities of cancer biology inevitably complicate any triumphant narrative, as the recent American Society for Clinical Oncology meeting showed for checkpoint inhibitors like the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?